CD36 and Other metabolic disease: Collectively, these results support future studies to identify potentially cohesive mechanisms underlying lipoprotein lipase- and CD36-mediated nerve injury in metabolic disease (Vincent et al., 2009), and their potential as therapeutic targets for PN treatment.